Clinical Trial Update: Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study of Xyotax (CT-2103) in patients with metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Xyotax (CT-2103)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED